Publikace obsahuje biografický rozhovor s Josefem Jonášem, českým lékařem, ve kterém hovoří o tradičním přírodním lékařství a o svém životě.; „Doktor tady není jen od toho, aby léčil, ale aby zejména předcházel nemocem.“ MUDr. Josefa Jonáše by bylo nejlépe ozdobit přívlastkem „PAN PRVNÍ“ anebo ho označit za „GÉNIA PŘÍRODNÍ MEDICÍNY“. Zeptáte se – proč? Doktor Jonáš náleží k nejznámějším světovým badatelům a popularizátorům v oblasti přírodní medicíny, jíž se věnuje plných pětapadesát let. Po absolutoriu lékařství a psychiatrické praxi začínal studiem akupunktury a dalších diagnostických léčebných metod. V pozici primáře psychiatrie v nemocnici v Chomutově dal po sedmnácti letech vale klasické medicíně a obrátil se směrem k jejímu protipólu, medicíně přírodní. Už jako mladý lékař začal intenzivně studovat starou čínskou medicínu, ájurvédu neboli starou indickou medicínu, evropské i české bylinářství a nejrůznější přírodní metody léčby od starověku po současnost. Přečetl stovky knih, a když nastala sametová revoluce, byl první (!), kdo si založil vlastní soukromou ordinaci. Jeho jméno bylo počátkem 90. let tak známé, že se před jeho legendární ordinací v pražské Týnské uličce řadili lidé do dlouhé fronty. Jonášovy knihy – Křížovka života a Tajenka života I. a II. – se staly bestsellery ve statisícových nákladech. Jako vědec a lékař zaměřený na výzkum zejména staré čínské medicíny postupně dospěl k objevu originální „Metody kontrolované a řízené detoxikace organismu“, která je v podstatě takovým malým zázrakem: zbaví člověka toxinů, kterými se naše tělo zanáší z vnějšího prostředí, z potravy i z vlastního organismu, pokud nám dobře nefunguje zejména střevní mikrobiom. Jonášova detoxikace nás zbaví jedů, které jsou základní příčinou nemocí. Je to něco podobného, jako když uklízíme byt. Nenecháváme v něm povalovat prach, umýváme ledničku, pračku, toaletu. Zatímco klasická medicína pouze léčí příznaky nemocí a farmaceutickými přípravky usiluje o vyléčení pacienta, metoda doktora Jonášova léčí příčiny nemocí. Dívá se totiž na člověka celostním pohledem jako na živou bytost, v níž vše se vším souvisí – fyzické s psychickým – a vztahy mezi orgány jsou jasně definovány: řídící orgán ovlivňuje podřízený a naopak. Je známo, že lidský organismus je schopen poradit si s devadesáti procenty všech nemocí, pokud ovšem funguje jeho imunitní systém, jak má. Doktor Jonáš dnes, ve svých osmdesáti letech, dovedl svou metodu k dokonalosti. Pomohla mu k tomu digitalizace a objevení možnosti programovat lidský mozek tak, aby nebyl zatěžován tím nejhorším, čím současné moderní lidstvo trpí - stresem a úzkostí. Mimo jiné vynalezl úžasné preparáty, které mohou pomoci s našimi dvěma nejčastějšími zdravotními problémy: s vysokým krevním tlakem a vysokou hladinou cholesterolu. Kniha mapuje životní pouť jubilanta MUDr. Josefa Jonáše v celé jeho šíři, nevyhýbá se ani jeho prohrám, a naopak zvýrazňuje úspěchy a velké počiny velkého lékaře-hybatele a vizionáře v oblasti přírodní medicíny. Výpravná publikace je poctou průkopníkovi, který nikdy neměl na růžích ustláno, holdem mezinárodně uznávanému vědci s mnoha prvky jedinečnosti a nebojíme se uvést – rovněž geniality s vášnivou a vědomou touhou narovnávat lidské zdraví a pomáhat člověku tam, kde klasická medicína nestačí a selhává. Autorizovaná kniha.

• Keywords
• detoxikace organismu,
• MeSH
• History, 20th Century MeSH
• History, 21st Century MeSH
• Holistic Health MeSH
• Complementary Therapies history   MeSH
• Physicians history   MeSH
• Medicine, Traditional history   MeSH
• Check Tag
• History, 20th Century MeSH
• History, 21st Century MeSH
• Publication type
• Interview MeSH
• Geographicals
• Czech Republic MeSH

• Conspectus
• Fyzioterapie. Psychoterapie. Alternativní lékařství
• Biografie
• NML Fields
• dějiny lékařství
• alternativní lékařství
• akupunktura a tradiční medicína

• About
• Jonáš, Josef, 1945-2025 Authority

• Keywords
• edukace sestrou,
• MeSH
• Surveys and Questionnaires MeSH
• Patient Satisfaction MeSH
• Kidney Transplantation MeSH
• Patient Education as Topic MeSH
• Nurses MeSH

The small-molecule alkaloid halofuginone (HF) is obtained from febrifugine. Recent studies on HF have aroused widespread attention owing to its universal range of noteworthy biological activities and therapeutic functions, which range from parasite infections and fibrosis to autoimmune diseases. In particular, HF is believed to play an excellent anticancer role by suppressing the proliferation, adhesion, metastasis, and invasion of cancers. This review supports the goal of demonstrating various anticancer effects and molecular mechanisms of HF. In the studies covered in this review, the anticancer molecular mechanisms of HF mainly included transforming growth factor-β (TGF-β)/Smad-3/nuclear factor erythroid 2-related factor 2 (Nrf2), serine/threonine kinase proteins (Akt)/mechanistic target of rapamycin complex 1(mTORC1)/wingless/integrated (Wnt)/β-catenin, the exosomal microRNA-31 (miR-31)/histone deacetylase 2 (HDAC2) signaling pathway, and the interaction of the extracellular matrix (ECM) and immune cells. Notably, HF, as a novel type of adenosine triphosphate (ATP)-dependent inhibitor that is often combined with prolyl transfer RNA synthetase (ProRS) and amino acid starvation therapy (AAS) to suppress the formation of ribosome, further exerts a significant effect on the tumor microenvironment (TME). Additionally, the combination of HF with other drugs or therapies obtained universal attention. Our results showed that HF has significant potential for clinical cancer treatment.

• Publication type
• Journal Article MeSH
• Review MeSH

BACKGROUND AND OBJECTIVE: While prostate cancer (PCa) incidence and mortality rates continue to rise, early detection of PCa remains highly controversial, and the research landscape is rapidly evolving. Existing systematic reviews (SRs) and meta-analyses (MAs) provide valuable insights, but often focus on single aspects of early detection, hindering a comprehensive understanding of the topic. We aim to fill this gap by providing a comprehensive SR of contemporary SRs covering different aspects of early detection of PCa in the European Union (EU) and the UK. METHODS: On June 1, 2023, we searched four databases (Medline ALL via Ovid, Embase, Web of Science, and Cochrane Central Register of Controlled Trials) and Google Scholar. To avoid repetition of previous studies, only SRs (qualitative, quantitative, and/or MAs) were considered eligible. In the data, common themes were identified to present the evidence systematically. KEY FINDINGS AND LIMITATIONS: We identified 1358 citations, resulting in 26 SRs eligible for inclusion. Six themes were identified: (1) invitation: men at general risk should be invited at >50 yr of age, and testing should be discontinued at >70 yr or with <10 yr of life expectancy; (2) decision-making: most health authorities discourage population-based screening and instead recommend a shared decision-making (SDM) approach, but implementation of SDM in clinical practice varies widely; decision aids help men make more informed and value-consistent screening decisions and decrease men's intention to attempt screening, but these do not affect screening uptake; (3) acceptance: facilitators for men considering screening include social prompting by partners and clinician recommendations, while barriers include a lack of knowledge, low-risk perception, and masculinity attributes; (4) screening test and algorithm: prostate-specific antigen-based screening reduces PCa-specific mortality and metastatic disease in men aged 55-69 yr at randomisation if screened at least twice; (5) harms and benefits: these benefits come at the cost of unnecessary biopsies, overdiagnosis, and subsequent overtreatment; and (6) future of screening: risk-adapted screening including (prebiopsy) risk calculators, magnetic resonance imaging, and blood- and urine-based biomarkers could reduce these harms. To enable a comprehensive overview, we focused on SRs. These do not include the most recent prospective studies, which were therefore incorporated in the discussion. CONCLUSIONS AND CLINICAL IMPLICATIONS: By identifying consistent and conflicting evidence, this review highlights the evidence-based foundations that can be built upon, as well as areas requiring further research and improvement to reduce the burden of PCa in the EU and UK. PATIENT SUMMARY: This review of 26 reviews covers various aspects of prostate cancer screening such as invitation, decision-making, screening tests, harms, and benefits. This review provides insights into existing evidence, highlighting the areas of consensus and discrepancies, to guide future research and improve prostate cancer screening strategies in Europe.

• MeSH
• Early Detection of Cancer * MeSH
• European Union * MeSH
• Humans MeSH
• Prostatic Neoplasms * diagnosis   MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Publication type
• Journal Article MeSH
• Review MeSH
• Geographicals
• United Kingdom MeSH

• MeSH
• Museums MeSH
• Art MeSH
• Persons with Visual Disabilities MeSH
• Publication type
• Catalog MeSH
• Exhibition MeSH

• Conspectus
• Muzea. Muzeologie. Muzejnictví. Výstavy
• NML Fields
• knihovnictví, informační věda a muzeologie
• oftalmologie

Publikace obsahuje rozhovory, ve kterých lidé sdílejí své zkušenosti s vitro fertilizací v Česku v posledních letech. Určeno široké veřejnosti.; Tohle není jen kniha o IVF. Je to svědectví o odvaze, naději, zármutku i síle. Novinářka Lucie Ptáčková přináší rozhovory s těmi, které spojuje zkušenost s umělým oplodněním. Ať už mají za sebou negativní testy, potraty či porod mrtvého dítěte, ať už se dočkali svého potomka, nebo snahu o něj opustili – jsou to hrdinové. Čekejte bolest, smích i otevřenost, která místy bere dech. Pokud zrovna nesete těžký batoh IVF, či jste ho už odložili, ale stopy po popruzích budete mít už navždy – tahle kniha je pro vás.

• MeSH
• History, 20th Century MeSH
• History, 21st Century MeSH
• Fertilization in Vitro * MeSH
• Parents MeSH
• Check Tag
• History, 20th Century MeSH
• History, 21st Century MeSH
• Publication type
• Interview MeSH
• Geographicals
• Czech Republic MeSH

• Conspectus
• Gynekologie. Porodnictví
• NML Fields
• reprodukční lékařství

The honeybee (Apis mellifera) is a key pollinator critical to global agriculture, facing threats from various stressors, including the ectoparasitic Varroa mite (Varroa destructor). Previous studies have identified shared bacteria between Varroa mites and honeybees, yet it remains unclear if these bacteria assemble similarly in both species. This study builds on existing knowledge by investigating co-occurrence patterns in the microbiomes of both Varroa mites and honeybees, shedding light on potential interactions. Leveraging 16S rRNA datasets, we conducted co-occurrence network analyses, explored Core Association Networks (CAN) and assess network robustness. Comparative network analyses revealed structural differences between honeybee and mite microbiomes, along with shared core features and microbial motifs. The mite network exhibited lower robustness, suggesting less resistance to taxa extension compared to honeybees. Furthermore, analyses of predicted functional profiling and taxa contribution revealed that common central pathways in the metabolic networks have different taxa contributing to Varroa mites and honeybee microbiomes. The results show that while both microbial systems exhibit functional redundancy, in which different taxa contribute to the functional stability and resilience of the ecosystem, there is evidence for niche specialization resulting in unique contributions to specific pathways in each part of this host-parasite system. The specificity of taxa contribution to key pathways offers targeted approaches to Varroa microbiome management and preserving honeybee microbiome. Our findings provide valuable insights into microbial interactions, aiding farmers and beekeepers in maintaining healthy and resilient bee colonies amid increasing Varroa mite infestations.

• MeSH
• Bacteria * classification   genetics   isolation & purification   MeSH
• Microbiota * MeSH
• RNA, Ribosomal, 16S genetics   MeSH
• Varroidae * microbiology   MeSH
• Bees microbiology   parasitology   MeSH
• Animals MeSH
• Check Tag
• Animals MeSH
• Publication type
• Journal Article MeSH

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) with neoadjuvant embolization is a treatment strategy for brain arteriovenous malformations (AVMs), especially for those with large nidal volume or concomitant aneurysms. The aim of this study was to assess the effects of pre-SRS embolization in AVMs with an associated intracranial aneurysm (IA). METHODS: The International Radiosurgery Research Foundation AVM database from 1987 to 2018 was retrospectively reviewed. SRS-treated AVMs with IAs were included. Patients were categorized into those treated with upfront embolization (E + SRS) vs stand-alone SRS (SRS). Primary end point was a favorable outcome (AVM obliteration + no permanent radiation-induced changes or post-SRS hemorrhage). Secondary outcomes included AVM obliteration, mortality, follow-up modified Rankin Scale, post-SRS hemorrhage, and radiation-induced changes. RESULTS: Forty four AVM patients with associated IAs were included, of which 23 (52.3%) underwent pre-SRS embolization and 21 (47.7%) SRS only. Significant differences between the E + SRS vs SRS groups were found for AVM maximum diameter (1.5 ± 0.5 vs 1.1 ± 0.4 cm 3 , P = .019) and SRS treatment volume (9.3 ± 8.3 vs 4.3 ± 3.3 cm 3 , P = .025). A favorable outcome was achieved in 45.4% of patients in the E + SRS group and 38.1% in the SRS group ( P = .625). Obliteration rates were comparable (56.5% for E + SRS vs 47.6% for SRS, P = .555), whereas a higher mortality rate was found in the SRS group (19.1% vs 0%, P = .048). After adjusting for AVM maximum diameter, SRS treatment volume, and maximum radiation dose, the likelihood of achieving favorable outcome and AVM obliteration did not differ between groups ( P = .475 and P = .820, respectively). CONCLUSION: The likelihood of a favorable outcome and AVM obliteration after SRS with neoadjuvant embolization in AVMs with concomitant IA seems to be comparable with stand-alone SRS, even after adjusting for AVM volume and SRS maximum dose. However, the increased mortality among the stand-alone SRS group and relatively low risk of embolization-related complications suggest that these patients may benefit from a combined treatment approach.

• MeSH
• Adult MeSH
• Endovascular Procedures methods   MeSH
• Intracranial Aneurysm * therapy   MeSH
• Intracranial Arteriovenous Malformations * therapy   surgery   MeSH
• Middle Aged MeSH
• Humans MeSH
• Neoadjuvant Therapy * methods   MeSH
• Radiosurgery * methods   adverse effects   MeSH
• Retrospective Studies MeSH
• Aged MeSH
• Embolization, Therapeutic * methods   MeSH
• Treatment Outcome MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Comparative Study MeSH

Cohort studies are a robust analytical observational study design that explore the difference in outcomes between two cohorts, differentiated by their exposure status. Despite being observational in nature, they are often included in systematic reviews of effectiveness, particularly when randomized controlled trials are limited or not feasible. Like all studies included in a systematic review, cohort studies must undergo a critical appraisal process to assess the extent to which a study has considered potential bias in its design, conduct, or analysis. Critical appraisal tools facilitate this evaluation. This paper introduces the revised critical appraisal tool for cohort studies, completed by the JBI Effectiveness Methodology Group, who are currently revising the suite of JBI critical appraisal tools for quantitative study designs. The revised tool responds to updates in methodological guidance from the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group and reporting guidance from PRISMA 2020, providing a robust framework for evaluating risk of bias in a cohort study. Transparent and rigorous assessment using this tool will assist reviewers in understanding the validity and relevance of the results and conclusions drawn from a systematic review that includes cohort studies. This may contribute to better evidence-based decision-making in health care. This paper discusses the key changes made to the tool, outlines justifications for these changes, and provides practical guidance on how this tool should be interpreted and applied by systematic reviewers.

• MeSH
• Cohort Studies MeSH
• Humans MeSH
• Research Design * standards   MeSH
• Bias * MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH

The topic of the diagnosis of phaeochromocytomas remains highly relevant because of advances in laboratory diagnostics, genetics, and therapeutic options and also the development of imaging methods. Computed tomography still represents an essential tool in clinical practice, especially in incidentally discovered adrenal masses; it allows morphological evaluation, including size, shape, necrosis, and unenhanced attenuation. More advanced post-processing tools to analyse digital images, such as texture analysis and radiomics, are currently being studied. Radiomic features utilise digital image pixels to calculate parameters and relations undetectable by the human eye. On the other hand, the amount of radiomic data requires massive computer capacity. Radiomics, together with machine learning and artificial intelligence in general, has the potential to improve not only the differential diagnosis but also the prediction of complications and therapy outcomes of phaeochromocytomas in the future. Currently, the potential of radiomics and machine learning does not match expectations and awaits its fulfilment.

• MeSH
• Pheochromocytoma * diagnostic imaging   MeSH
• Humans MeSH
• Adrenal Gland Neoplasms * diagnostic imaging   MeSH
• Paraganglioma * diagnostic imaging   MeSH
• Tomography, X-Ray Computed methods   MeSH
• Image Processing, Computer-Assisted methods   MeSH
• Radiomics MeSH
• Machine Learning MeSH
• Artificial Intelligence MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Review MeSH